Saurabh Saha Biography and Net Worth

Director of Clarivate

Saurabh Saha, M.D. Ph.D. has been a member of the Clarivate Board of Directors since May 2023. Dr. Saha brings over 20 years of experience in the health and life sciences field and has served as the Chief Executive Officer of Centessa Pharmaceuticals since January 2021. Prior to joining Centessa, he was Senior Vice President of Research & Development and Global Head of Translational Medicine for Bristol Myers Squibb Company from 2017 to January 2021, where he led translational medicine research and development across all therapeutic areas (hematology, oncology, cardiovascular, immunosciences, fibrosis and neuroscience) spanning discovery, development and commercialization. From 2015 to 201, Dr. Saha was a venture partner at Atlas Venture Life Science Advisors, LLC. Prior to that he served as President and Chief Executive Officer of Delinia, Inc., a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Earlier in his career, he led the New Indications Discovery Unit at Novartis Institutes for Biomedical Research, Inc. and was a strategic consultant with McKinsey & Company, providing strategic advice for drug discovery research at the world’s top biotech and pharmaceutical companies. Dr. Saha is currently a member of the board of directors of Centessa Pharmaceuticals. He is an associate member and global clinical scholar at Harvard Medical School. Dr. Saha received a B.Sc. in Biology with Honors from California Institute of Technology, an M.Sc. in Biochemistry from Oxford University, and an M.D. and Ph.D. from The Johns Hopkins University School of Medicine. Over the course of his career, he has published over 100 papers and patents (issued and pending).

What is Saurabh Saha's net worth?: The estimated net worth of Saurabh Saha is at least $2.91 million as of October 23rd, 2024. Dr. Saha owns 630,661 shares of Clarivate stock worth more than $2,907,347 as of November 8th. This net worth approximation does not reflect any other assets that Dr. Saha may own. Learn More about Saurabh Saha's net worth.
How do I contact Saurabh Saha?: The corporate mailing address for Dr. Saha and other Clarivate executives is 160 Blackfriars Road, London X0, SE1 8EZ. Clarivate can also be reached via phone at 442074334000 and via email at [email protected]. Learn More on Saurabh Saha's contact information.
Has Saurabh Saha been buying or selling shares of Clarivate?: Saurabh Saha has not been actively trading shares of Clarivate during the last ninety days. Most recently, Saurabh Saha sold 17,646 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $6.75, for a transaction totalling $119,110.50. Following the completion of the sale, the director now directly owns 23,741 shares of the company's stock, valued at $160,251.75. Learn More on Saurabh Saha's trading history.
Who are Clarivate's active insiders?: Clarivate's insider roster includes Mukhtar Ahmed (Insider), Richard Hanks (CFO), Richard Roedel (Director), Saurabh Saha (Director), James Samson (Insider), Andrew Snyder (Director), Bar Veinstein (Insider), and Sheryl von Bluchder (Director). Learn More on Clarivate's active insiders.
Are insiders buying or selling shares of Clarivate?: In the last year, Clarivate insiders bought shares 1 times. They purchased a total of 28,938 shares worth more than $158,869.62. In the last year, insiders at the sold shares 3 times. They sold a total of 197,646 shares worth more than $1,379,110.50. The most recent insider tranaction occured on October, 15th when insider Bar Veinstein sold 60,000 shares worth more than $420,000.00. Insiders at Clarivate own 23.1% of the company. Learn More about insider trades at Clarivate.
Information on this page was last updated on 10/15/2024.

Saurabh Saha Insider Trading History at Clarivate

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/30/2024	Sell	17,646	$6.75	$119,110.50	23,741

Saurabh Saha Buying and Selling Activity at Clarivate

Clarivate Company Overview

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.

Today's Range

Now: $4.59

$4.55

$4.73

50 Day Range

MA: $6.60

$4.68

$7.10

2 Week Range

Now: $4.59

$4.55

$9.60

Volume

4,274,084 shs

Average Volume

4,282,173 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.